.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC20_Netakimab.Netakimab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC20_Netakimab.Netakimab| name: | Netakimab | |
| ATC code: | L04AC20 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 120 | mg |
| volume of distribution: | 5.7 | L |
| clearance: | 0.0117 | L/h |
| other parameters in model implementation | ||
Netakimab is a humanized IgG1 monoclonal antibody targeting interleukin-17A (IL-17A), used for the treatment of autoimmune inflammatory disorders such as moderate-to-severe plaque psoriasis and psoriatic arthritis. It is approved for clinical use in Russia and certain other countries.
Population pharmacokinetics in adult patients with moderate-to-severe plaque psoriasis and psoriatic arthritis; healthy volunteers and clinical use population; both sexes; typical adult population.
Erdes, S, et al., & Ivanov, R (2020). Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults. Clinical and experimental rheumatology 38(1) 27–34. PUBMED:https://pubmed.ncbi.nlm.nih.gov/31025924